Young Mania Rating Scale
Clinician-rated 11-item scale measuring severity of manic episodes. Widely used in bipolar disorder trials.
Score interpretation
Score 0–12: Minimal or no manic symptoms
→ Routine monitoring; adjust maintenance therapy if appropriate
Score 13–19: Mild mania or hypomania
→ Optimise mood stabiliser; increase outpatient contact
Score 20–24: Moderate manic episode (≥20 is the usual entry threshold in acute mania trials)
→ Pharmacotherapy adjustment; consider admission
Score ≥25: Severe manic episode (≥25 best identified 'markedly ill' or worse on CGI-BP; Lukasiewicz 2013)
→ Psychiatric admission; antipsychotic + mood stabiliser; risk assessment
Interpretation bands for the YMRS. Apply clinical judgement and local guidance.
References
- Young RC, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
- Lukasiewicz M, et al. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res. 2013;22(1):46-58.
Related
Curated clinical cross-links plus same-class fallbacks.
- Carbamazepine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Disorder
- Carbamazepine (Paediatric) · Antiepileptic — Focal Seizures / Trigeminal Neuralgia / Bipolar Disorder
- Lamotrigine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Depression
- Sodium Valproate · Antiepileptic / Mood stabiliser
- Valproic acid · Antiepileptic / mood stabiliser
- Lissamine Green 1% Eye Drops · Vital Dye — Ocular Surface Staining (Dry Eye Diagnosis)
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.